NCT03334604View on ClinicalTrials.gov

The Effect of a Multispecies Probiotic on Reducing the Incidence of Antibiotic-associated Diarrhoea in Children.

NACompletedINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

February 16, 2018

Primary Completion Date

May 13, 2021

Study Completion Date

May 13, 2021

Conditions
Antibiotic-associated Diarrhea
Interventions
DIETARY_SUPPLEMENT

Multispecies probiotic

Multispecies probiotic consisting of Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus acidophilus W55, Lactobacillus paracasei W20, Lactobacillus plantarum W62, Lactobacillus rhamnosus W71 and Lactobacillus salivarius W24 at a dose of 5x10\^9 Colony Forming Units (CFU), twice daily, orally.

OTHER

Placebo

Placebo identical in taste, smell and color to the multispecies probiotic.

Trial Locations (6)

1061

OLVG location West, Amsterdam

1092

OLVG location East, Amsterdam

1105

Amsterdam UMC, location AMC, Amsterdam

1081 HV

Amsterdam UMC, location VUmc, Amsterdam

55-100

Department of Paediatrics, St. Hedwig of Silesia Hospital, Trzebnica

02-091

Department of Paediatrics, The Medical University of Warsaw, Poland, Warsaw

All Listed Sponsors
collaborator

Winclove Probiotics B.V.

INDUSTRY

lead

Medical University of Warsaw

OTHER

NCT03334604 - The Effect of a Multispecies Probiotic on Reducing the Incidence of Antibiotic-associated Diarrhoea in Children. | Biotech Hunter | Biotech Hunter